All donor screening, recovery and tissue processing is performed by a tissue bank registered with the Food and Drug Administration (FDA) and accredited by the American Association of Tissue Banks (AATB).

Our experienced professionals have a clear understanding of physician and healthcare facility needs. We strive to bring safe, high quality, innovative biologics to the healthcare market that are capable of maximizing allograft performance. In 2003 the Research and Development center was established, which is a state of the art fully automated 120,000 sq. ft. facility to serve the needs of a now-global footprint to over 30 countries.

Quality Management System:

• ISO13485certified• ISO class 5 clean rooms• FDA registered, complies with 21 CFR Part 1270 and 1271 • AATB accredited

Products are in compliance with:

• FDA regulation, Title 21, Code of Federal Regulations Part 1271• Human Organs And Tissues Safety And Control Act [PartialmodificationonJanuary27,2005ActNo.7375]• Human Organs And Tissues Safety And Control Executive Order [PartialmodificationonJuly3,2006.DecreeofDepartmentofHealth&WelfareNo.363]• Human Organ And Tissue Safety And Control Decree [PartialmodificationonJune12,2006.PresidentialDecreeNo.19513]• DecreeNo.2005-16Food&DrugAdministrationNo.2005-16

Qua

lity

Con

trol

2

Product Inform

ation

3

OneFuse is a Patented combination of demineralized cortical bone, and a carrier. The carrier,in recent studies, “demonstrated advantageous properties in tissue engineering such as formation of pathways for induction of better cell migration, better delivery of nutrients and bioactive molecules to growing cells and better removal of their wastes, thus providing a better environment for tissue regeneration.” As a result OneFuse has a unique characteristic in that it has extremely high cohesiveness while having excellent hydrophilic qualities.

DBM Putty Benefits:• Donor testing exceeds FDA and AATB criteria• High osteoinductivity (Each lot tested by In Vitro Assay)• Each lot is tested for BMP’s and growth factors (ELISA)• Superior handling/molding characteristics• High cohesiveness• Excellent hydrophilic qualities• Easily mixed with complimentary biologics• Room temperature storage• Comes ready to use• Electron beam sterilization

DBM Gel Benefits:• Donor testing exceeds FDA and AATB criteria• High osteoinductivity (Each lot tested by In Vitro Assay)• Each lot is tested for BMP’s and growth factors (ELISA)• Excellent handling/flowable characteristics• High cohesiveness• Excellent hydrophilic qualities• Easily mixed with complimentary biologics• Room temperature storage• Comes ready to use• Electron beam sterilization

Indi

catio

ns

4

Orthopedic/Spine Surgery • Compensation and reconstruction of autograft bone• Spine fixation with adequate materials• Bone fixation and filling in various sizes and forms of bone defect• Spinal fusion

Dental SurgeryImplantological Indications• Extraction site• Ridge preservation• Sinus floor elevation• Socket preservation• Wall defect• Torus• Fenestration defect• Dehiscence defect• Reconstruction of maxillofacial defect

Contraindications

• Uncontrolled diabetes• Severe degenerative bone disease• Active or latent infection in or about the surgical site

• Oncology• Joint revision• Long bone trauma• Distal fracture• Small bone procedure• Maxillofacial defect

Periodontal Indications• Periodontal augmentation• Exposed implant• Periodontal defect• Esthetic augmentation

• Renal impairment• Vascular disease• Neurological disease

OneFuse is not intended to provide structural support of the bone during the healing processand the following circumstances:

Grow

th Factors

5

Each lot of OneFuse is tested for BMP’s and growth factors (ELISA)

Purpose:This report documents the results of a comparison between the in vitro assay and In vivo results for ten lots.

• Samples from the same ten lots were tested per Protocol: BMP-2 ELISA. Each donor lot was tested in triplicate• BMP-2 concentration was mainly affected by individual factors (gender, age, health condition of donors). As reported in the literature, BMP-2 induces new bone formation at both bony and non-bony sites. A dose-related response was observed and reported as well: higher doses of rhBMP-2 yielded a faster formation of cartilage and bone• The BMP-2 concentration of OneFuse was measured and a range of 42.48 ~ 123.50 ng BMP-2 in 1cc were detected by ELISA

Sero

logi

cal T

estin

g

Prior to donation all donor medical/social history is screened for medical conditions or diseases that would contraindicate the donation of tissue in accordance with the current regulations established by the FDA (21 CFR 1270) and standards set forth by AATB. All donor tissue utilized for processing is provided by recovery agencies registered with the FDA and accredited by AATB. Screening criteria exceeds requirements established by the FDA and AATB.

Serological tests are performed in accordance to FDA regulations and AATB standards.

Inaccordance ithregulationssetforth ytheFDAandstandards yAA ,donor loodsamplesarecollectedatthetimeofreco eryandserologicaltestingisperformedoneachtissuedonor see elo ya IAcertifiedlaboratory.

• Anti odiestothehumanimmunodeficiency irus,type1andtype2 anti-HI -1andanti-HI -2• Nucleic acid test (NAT) for HIV-1• Hepatitis B surface antigen (HBsAg)• otalanti odiestohepatitis coreantigen anti-H c-total,meaningIg andIg• Antibodies to the hepatitis C virus (anti-HCV)• Nucleic acid test (NAT) for HCV• Syphilis

6

Tissue Donor Selection/Screening

7

Clinically significant metabolic bone diseaseGonorrhea (clinically active) Illicit drug use, injected drugsLeprosy (Hansen’s disease)Polyarteritis nodosaRabiesRheumatoid arthritisSarcoidosisSystemic lupus erythematosusSystemic mycosis

Tuberculosis (clinically active)Active genital herpesCancer (see chart below)Encephalitis (clinically active)Endocarditis (clinically active)High risk behaviorIllicit drug use, non-injected drugsMeningitis (clinically active)Multiple sclerosisPoliomyelitis

Tissue cultures collected during the recovery process are tested for the following microbial contaminants:

• Aerobic• Anaerobic• Fungal

OneFuse additional screening:

Vira

l Ina

ctiv

atio

n an

d B

ioco

mpa

tibili

ty

Tissue processing procedures have been validated to inactivate and eliminate the following viruses:

• HI -1-Humanimmunodeficiency irustype1• BHV - Bovine herpes virus • BVDV - Bovine viral diarrhea virus• HAV - Hepatitis A virus• PPV - Porcine parvovirus

OneFuse has undergone and passed the following series of standard tests relating to its biocompatibility:

Test Test OverviewISO 10993-5 To determined whether leachables extracted from the material would cause cytotoxicityISO 10993 Part 10 2002(E) Tests for Irritation and Delayed-type HypersensitivityISO 10993 Part 10 2002(E) Tests for Irritation and Delayed-type HypersensitivityISO10993 Part 11 2002(E) Test for Systemic ToxicityUSP 28[88] To evaluate the local effect of implanted OneFuse samples in the paravertebral muscleISO 10993-6 To evaluate the biocompatibility and local effect of OneFuse over a 12 week periodISO 10993 Part 3 Test for Genotoxicity, Carcinogenicity and Reproductive Toxicity.ISO 10993-4 Test the interaction of OneFuse samples with rabbit bloodISO 10993-12 To determine the level of endotoxin in the leachables extracted from the testing material

Cytotoxicity

Maximization/Hypersensitivity Testing

Irritation/Intracutaneous Reactivity Testing

Acute Systemic Toxicity Study in Mouse

Muscle Implantation/Biological Suitability Testing in Rabbits

Implantation Test in Rabbit Bone

Genotoxicity/Bacterial Reverse Mutation Assay (Ames Test)

Hemolysis Testing

Endotoxin Testing

8

Carrier Inform

ation

Carboxymethyl Cellulose (CMC)

Issodiumsaltofcar o ymethylcellulose.Itisderi edfromcellulose, hichismade ater-solu le yachemicalreaction. he ater-solu ilityisachie ed yintroducingcar o ymethylgroupsalongthecellulosechain, hichma eshydrationofthemoleculepossi le. isusedasa iscositymodifierorthic ener,andtosta ili e emulsions in various products. CMC is also known for its excellent water retaining capacity.

Studiesha esho nthatporous sca oldsdemonstratedad antageouspropertiesintissueengineeringsuchasformationofpath aysforinductionof ettercellmigration, etterdeli eryofnutrientsand ioacti emoleculestogro ingcellsand etterremo aloftheir astes,thuspro idinga etteren ironmentfortissueregeneration.[1]

1.H ang ,SantS, asaeli , achouieNN, amanian , eeSH,etal.Fa ricationofthree-dimensionalporouscell-ladenhydrogelfortissue engineering. Biofabrication. 2010;2:035003 (12 pp)

9

Fusi

on S

tudy

3XUSRVH�hestudy�asconductedto�erifythee�ecti�enessofspinalfusion�ithOneFuseanditsa�ilitytostimulate new bone formation.

6XPPDU\The spinal fusion models of rabbits were prepared following posterolateral intertransverse process arthrodesis bilaterally at L4-L5 section of the lumbar vertebrae. Equivalent amounts of OneFuse putty and gel and the industry leading DBM (control) were implanted into each model. The ability of OneFuse to stimulate new bone formation andinter�odyspinalfusion�ase�aluatedat4,8and13�ee�safterimplantation�yconductingalongitudinalradiologice�aluation,�iomechanicalandhistologytest.�hera��itsmodels�eree�aluatedforradiologicfindings,fusionrate,�iomechanicalstrengthandhistologicalfindings�graftmaterialresiduerate,ne��oneformationrate�.The results indicate biocompatibility and proved a gradual density growth along with successful bone remodeling. Fusion�aso�ser�edafter13�ee�sinthe�4���section.Inhistologicale�aluation,compact�onecontinuity�asnoted following a progressive activation of new osteoid tissue and bone marrow cavity formation.

&RQFOXVLRQOneFusehasane�ui�alente�ect�hencomparedtotheindustryleading���.

4 weeks 13 weeks

Radiographs of a rabbit spine after posterolateral lumbar arthrodesis using OneFuse

10

4 Weeks 13 Weeks

Osteoinductivity Study

Pu seThe study was conducted to evaluate OneFuse originating from multiple donors.

u yIn Vitro Assay• heOneFusesamplesusedforthise aluationoriginatedfromtendi erentdonors. heunits eresterili ed y electron beam• Samples from the same ten lots were tested per Protocol: BMP-2 ELISA. Each donor lot was tested in triplicate• P-2concentration asmainlya ected yindi idualfactors genderandage .Asreportedintheliterature, BMP-2 induces new bone formation at both bony and non-bony sites. [6.1] A dose-related response was observed and reported as well: higher doses of rhBMP-2 yielded a faster formation of cartilage and bone• The BMP-2 concentration of OneFuse was measured

n • Samples from the same ten lots were implanted per Protocol: In vivo Osteoinductivity Assessment using an Ectopic Bone Formation Model. Each lot of tissue was implanted into three mice with each mouse receiving approximately 0.3cc of OneFuse• After28days,themice eresacrificed• Slides were prepared and examined using various methods including immunology and histology

n us nsOneFuse astransplantedinthehipmuscleofanathymicrat, and several histological tests were performed for e aluationofosteoinducti ea ility. onse uently,therecruitmentofosteo lastsandosteoclastsinthesites hich contribute to osteogenesis were observed. The osteoblasts which were observed in the site might be interpreted as DBM being degraded to form new bone. The results show that OneFuse has high osteoinductive capacity in a mousemodel,contri utingtone oneformationin one-defecti eregions.

11

Each lot is tested for osteoinductivity (In Vitro Assay) Each lot of OneFuse is tested for BMP’s and growth factors (ELISA)

ste st B ste st une e nne t e t ssue e ne B

Ord

erin

g In

form

atio

n

TMtisucor

P e se u t e s y P ne

: e s t su:

P ne: e t

1.0 TCDBM-P1

3.0 TCDBM-P3

5.0 TCDBM-P5

10.0 TCDBM-P10

1.0 TCDBM-G1

3.0 TCDBM-G3

5.0 TCDBM-G5

10.0 TCDBM-G10

Volume (cc) Order Number

Volume (cc) Order Number

12

*Note: Price List, Terms & Conditions on Separate Handouts

*Note: Price List, Terms & Conditions on Separate Handouts

GEL

PUTTY

4819 Emperor Blvd. Suite 400 | Research Triangle Park | Durham, NC 27703

phone: 844-TISUCOR | 844-847-8267 | fax: 844-497-9800tisucor.com